May 30 (SeeNews) - Bosnian pharmaceuticals producer Bosnalijek [SAJ:BSNLR] said it is has signed a cooperation agreement with the Netherlands-registered global healthcare company Mylan.
Under the agreement, the two companies will work on joint projects, the first of which envisages the marketing of seven pharmaceutical products, Bosnalijek said in a statement earlier this week.
This partnership will be later expanded into different areas, primarily those that will enable access to new molecules, therapeutic areas and a better market position in line with the latest pharmacotherapy trends.
"The future in pharmaceutical industry belongs to oncology and immuno-oncology therapies, as well as biological and biosimilar drugs. The companies that master this portfolio will ensure a strong competitive advantage," Bosnalijek CEO Nedim Uzunovic said.
"Therefore, through this cooperation, we focused on medicines that will help us strengthen our position in new therapeutic areas like type one diabetes, asthma, haematology, oncology and cardiology."
Mylan is active in 165 countries and territories, with a portfolio of over 7,500 products (including biosimilars) and annual revenue of some $11.4 billion (10.2 billion euro) in 2018.
($=0.897973 euro)